adiponectin. We also investigated whether these biomarkers correlated with various demographic, clinical and laboratory markers. Methods We treated 37 RA patients with either etanercept (ETN) or certolizumab pegol (CZP) in a 12 month follow-up study. Assessments were performed at baseline, and 3, 6 and 12 months after treatment initiation. Serum chemerin and adiponectin concentrations were measured by commercially available ELISA kits (R and D System, MN and USA). PON1 and arylesterase activities were measured by spectrophotometry. In addition, age, disease duration, disease activity (DAS28), CRP, anti-CCP, IgM rheumatoid factor and plasma lipid levels were also assessed. Arterial flow-mediated vasodilation (FMD), carotid intima-media thickness (cIMT) and arterial pulse-wave velocity (PWV) were assessed by ultrasound. Results Anti-TNF treatment resulted in a significant decrease in the levels of chemerin (p<0.001) and adiponectin (p<0.007) after 12 months. There were no significant changes in the levels of other metabolic biomarkers. We found the following correlations between the baseline values: the PON1 levels correlated with the age of patients (R=0.466, p=0.004). The adiponectin correlated with the disease activity (R=0.385, p=0.030), HDL-C (R=0.417, p=0.012) and the triglyceride levels (R=0.481, p=0.003). The total cholesterol correlated with the PWV (R=0.449, p=0.021) and the levels of the LDL-C (R=0.911, p<0.001). Introduction Systemic sclerosis (SSc) is a severe disease characterised by auto-immunity, vasculopathy and excessive fibrosis of connective tissues. The pathophysiology of SSc is still poorly understood, but its symptoms imply a role for dysregulated transforming growth factor b (TGFb) signalling because this cytokine is known to regulate vascular and connective tissue biology. TGFb circulates in blood in an inactive latent form bound to latency associated peptide and latent TGFb binding proteins. This latent TGFb has to be activated before it can become bioactive. With the use of a bioassay TGFb's bioactivity can be measured in complex mixtures like serum. This is not possible with an ELISA because this technique does not take (cellular) activation processes into account. Objectives To determine the bioactivity of TGFb in SSc serum compared to that of healthy control serum. Methods Serum was collected of 10 SSc patients and 10 age and sex matched healthy controls. Primary human fibroblasts of 3 donors were transduced with CAGA 12 -luc which produces luciferase in response to TGFb/Smad3 or BRE-luc which produces luciferase in response to BMP/Smad1/5. These cells were treated with 10% serum for 16 hour and luciferase activity was measured. To activate all TGFb, sera were treated with 4M HCl for 1 hour at RT, after which pH was normalised with 4M NaOH. Controls were treated with HCl and NaOH simultaneously. To verify that TGFb signalling was measured in this reporter assay, sera were treated with antiTGFb1/2/3 for 1 hour at RT before use. Results Control sera significantly induced reporter activity by 4.5-fold. However, SSc sera only induced a 2.5-fold increase in luciferase activity, indicating significantly lower bioactivity of TGFb (p<0.0001). This difference was not due to a difference in total TGFb levels; after activation of all TGFb both HC and SSc sera induced a similar 6-fold increase in signal strength. These data show that in HC sera approximately 75% of all TGFb is bioactive compared to only 42% in SSc. Addition of anti-TGFb1/2/3 inhibited all CAGA 12 -luc reporter activity (p<0.0001) of both HC and SSc serum, and of both acidified and not acidified sera (p<0.0001), showing that our bioassay is indeed TGFb-dependent. To investigate if reduced bioactivity is a more general phenomenon we measured BMP activity. BMP proteins are structurally closely related to TGFb and also circulate in inactive form. Both HC and SSc sera induced a similar 8-fold increase in BRE-luc activity, and this activity was increased to a 16-fold induction after acidification for both groups. BMPs in SSc sera are thus not less bioactive. This illustrates the uniqueness of our observation on TGFb bioactivity. Conclusions TGFb in SSc serum is less bioactive than in control serum whereas BMPs are not less bioactive. Introduction Interleukin-17A (IL-17), tumour necrosis factor-a (TNFa) and IL-6 are pro-inflammatory cytokines involved in many autoimmune and inflammatory diseases including rheumatoid arthritis. Because most acute-phase proteins are produced by the liver, the hepatic response plays an important role in systemic inflammation. By producing chemokines such as CCL-20 that attract Th17 cells, hepatocytes can recruit mononuclear cells in liver, which leads to chronic hepatitis. Objectives To determine the effect of the IL-17/TNFa combination and the contribution of hepatocyte-peripheral blood mononuclear cell (PBMC) interactions in the hepatic inflammatory response. Methods Human HepaRG cell line and primary human hepatocytes (PHH) were cultured with or without IL-6, anti-IL-6 receptor (anti-IL-6R) antibody, IL-17 and/or TNFa. For co-cultures, PBMC from healthy donors activated or not with phytohemagglutinin (PHA) were added on hepatocytes at a 5:1 ratio. Transwell system was used to study the contribution of the direct cell-cell contact. Cytokine expression and production were quantified by qRT-PCR and ELISA respectively and 
